The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Lamivudine Treatment Is Beneficial in Patients With Severely Decompensated Cirrhosis and Actively Replicating Hepatitis B Infection Awaiting Liver Transplantation: A Comparative Study Using A Matched, Untreated Cohort
Abstract
Uncontrolled studies have suggested a beneficial effect of lamivudine in patients with decompensated cirrhosis caused by replicating hepatitis B virus (HBV). We analyzed the outcome of lamivudine treatment in 23 consecutive patients with severely decompensated HBV–cirrhosis defined as a Child–Pugh–Turcotte (CPT) score of ≥10, and compared with a historical untreated control group of 23 patients matched for age, gender, and baseline CPT score. Significant clinical response, defined as a decrease in the CPT score by ≥3 points, was observed in 14 of 23 (60.9%) treated patients versus none of the controls (P < .0001). The median change in CPT scores was -3.0 (range, -6 to +3) in the treated group versus +1.0 in the controls (range, -1 to +2) (P = .016). Orthotopic liver transplantation (OLT) was performed in 34.8% of treated patients (median, 3.5; range, 1–32 months), versus 73.9% of controls (median, 3.0; range, 1–14 months) (P = .04). Excluding transplanted patients, there were no deaths in the treated group versus 6 deaths in the control group (P = .009). Time to death or OLT was significantly longer in treated patients than in controls (P < .001). Two patients developed lamivudine resistance after 9 and 12 months, respectively. Our results suggest that lamivudine significantly improves hepatic function in over half of the patients with decompensated cirrhosis and replicating HBV, and may confer a survival advantage. However, the small sample size and the use of a retrospective control cohort preclude drawing definitive conclusions. Expedited OLT remains the only viable treatment for lamivudine nonresponders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
LAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
Villeneuve, J.-P., Condreay, L. D., Willems, B., Pomier-Layrargues, G., Fenyves, D., Bilodeau, M., Leduc, R., Peltekian, K., Wong, F., Margulies, M., et al. (2000) · Hepatology · doi:10.1002/hep.510310130 · Cited by 410
Lamivudine resistance inimmunocompetent chronic hepatitis B
Honkoop, P., Niesters, H. G. M., de Man, R. A., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80476-x · Cited by 271
Yao, F. Y., & Bass, N. M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80371-2 · Cited by 182
Self-citationBeneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
Kapoor, D., Guptan, R. C., Wakil, S. M., Kazim, S. N., Kaul, R., Agarwal, S. R., Raisuddin, S., Hasnain, S. E., & Sarin, S. K. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80372-4 · Cited by 143
Bain, V. G., Kneteman, N. M., Ma, M. M., Gutfreund, K. S., Shapiro, J., Fischer, K., Tipples, G. A., Lee, H., Jewell, L. D., & Tyrrell, D. L. (1996) · Transplantation · doi:10.1097/00007890-199611270-00013 · Cited by 133
Antiviral chemotherapy for the treatment of hepatitis b virus infections
Torresi, J., & LOCARNINI, S. A. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70008-4 · Cited by 125
INCREASED WAITING TIME FOR LIVER TRANSPLANTATION RESULTS IN HIGHER MORTALITY1
Everhart, J. E., Lombardero, M., Detre, K. M., Zetterman, R. K., Wiesner, R. H., Lake, J. R., & Hoofnagle, J. H. (1997) · Transplantation · doi:10.1097/00007890-199711150-00012 · Cited by 93
Cited by
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Dienstag, J. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801644 · Cited by 961
AASLD practice guidelines: Evaluation of the patient for liver transplantation†
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 939
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
The new liver allocation system: Moving toward evidence-based transplantation policy
Freeman, R. B., Wiesner, R. H., Harper, A., McDiarmid, S. V., Lake, J., Edwards, E., Merion, R., Wolfe, R., Turcotte, J., & Teperman, L. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.35927 · Cited by 724
Metadata
- Authors
- Yao, F. Y., Terrault, N. A., Freise, C., Maslow, L., & Bass, N. M.
- Venue
- Hepatology
- Published
- 2001-08
- Volume
- 34
- Issue
- 2
- Pages
- 411-416
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2003709460
- Cited by
- 268
- References
- 12
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lamivudine Treatment Is Beneficial in Patients With Severely Decompensated Cirrhosis and Actively Replicating Hepatitis B Infection Awaiting Liver Transplantation: A Comparative Study Using A Matched, Untreated Cohort. https://app.cochat.ai/papers/10.1053/jhep.2001.26512
- The paper
- Yao, F. Y., Terrault, N. A., Freise, C., Maslow, L., & Bass, N. M. (2001). Lamivudine Treatment Is Beneficial in Patients With Severely Decompensated Cirrhosis and Actively Replicating Hepatitis B Infection Awaiting Liver Transplantation: A Comparative Study Using A Matched, Untreated Cohort. Hepatology. https://doi.org/10.1053/jhep.2001.26512
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.